The therapeutic working group of the Lyme Borreliosis Foundation subjected the combined therapeutic scheme developed by Dr Béla Pál Bózsik to detailed examination.
First, the concept was tested in vitro, which resulted in the following publication:
IN VITRO ABX COMBINATIO 1990-91
The combinations were then tested in detail using the clinical database of a pharmaceutical company. These combinations had already been used in other areas and were well tolerated by the body.
Thus, clinical research could begin, with a 5-year follow-up of 250 patients. The following article reports on this:
The treatment has since been used in thousands of cases, with no serious adverse events other than the usual mild side effects.
The treatment was always administered on the recommendation of a physician, accompanied by weekly or biweekly laboratory tests and medical check-ups.
Complementary therapy, which began 3-4 weeks prior to treatment and continued throughout the treatment, helps to avoid side effects and promote rapid recovery:
SUPPLEMENTATIO PREPARATIO RECONVALESCENTIA
Documents in English:
Combined therapy clinical trial publication: Orvosi Hetilap Lyme therapy_EN
Supplementation therapy to an antibiotic regime: SUPPLEMENTATIO_GB
